ORIGINAL_ARTICLE
بررسی میزان انطباق مراقبتهای دوران بارداری ارائه شده در سه ماهه دوم و سوم بارداری با راهنمای استاندارد کشوری در مراکز بهداشتی درمانی اهواز، 1391
مقدمه: مراقبتهای دوران بارداری، اجرای صحیح اصولی است که با هدف حفظ سلامت مادر و تولد نوزاد سالم انجام میشود و اگر مراقبتهای دوران بارداری به طرز صحیح انجام نشود باعث افزایش زایمان زودرس، تولد نوزادان با وزن کم هنگام تولد و مرگ و میر مادر و نوزاد میشود، لذا مطالعه حاضر با هدف بررسی میزان انطباق مراقبتهای دوران بارداری ارائه شده با راهنمای استاندارد کشوری در مراکز بهداشتی درمانی شهرستان اهواز انجام شد. روشکار: این مطالعه توصیفی در سال 1391 بر روی 392 زن باردار مراجعه کننده به مراکز بهداشتی درمانی تابع دانشگاه علوم پزشکی جندی شاپور اهواز انجام شد. پس از کسب رضایتنامه کتبی از زنان باردار به مشاهده همزمان مراقبتهای ارائه شده دوران بارداری و تکمیل پرسشنامههای مربوطه پرداخته شد. تجزیه و تحلیل دادهها با استفاده از نرمافزار آماری SPSS (نسخه 18) انجام شد. یافتهها: مراقبت دوران بارداری ارائه شده در مراکز بهداشتی درمانی در 3/65% موارد انطباق ضعیف و در 7/34% موارد انطباق متوسط با استاندارد کشوری داشت. به تفکیک مراقبتها در سه ماهه دوم بارداری، در 3/66% موارد انطباق ضعیف، در 2/33% موارد انطباق متوسط و تنها در 5/0% موارد انطباق خوب و در سه ماهه سوم بارداری، در 3/77% موارد انطباق ضعیف و در 9/21% موارد انطباق متوسط با استاندارد کشوری مشاهده شد. نتیجه گیری: مراقبت دوران بارداری ارائه شده در مراکز بهداشتی درمانی، مطابق با استانداردهای کشوری نمیباشد و نیاز به کنترل میباشد.
https://ijogi.mums.ac.ir/article_7607_5d47d65be8c1cafd0122bf0bd254186f.pdf
2016-07-22
1
14
10.22038/ijogi.2016.7607
راهنمای استاندارد کشوری
مراقبت بارداری
مراکز بهداشتی درمانی
پروین
اسفندیارینژاد
1
کارشناس ارشد مامایی، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران.
AUTHOR
سلیمه
نظامیوند چگینی
2
کارشناس ارشد مامایی، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی تبریز، تبریز، ایران.
AUTHOR
شهناز
نجار
shanaznajar@yahoo.com
3
کارشناس ارشد مامایی، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران.
AUTHOR
معصومه
یارعلیزاده
4
کارشناس ارشد مامایی، مرکز تحقیقات ارتقاء سلامت باروری، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران
LEAD_AUTHOR
پوراندخت
افشاری
pafshary@yahoo.com
5
کارشناس ارشد مامایی، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران
AUTHOR
سمیرا
بیرانوند
6
کارشناس ارشد پرستاری، گروه پرستاری، دانشکده پرستاری و مامایی، مرکز تحقیقات مراقبت بیماریهای مزمن، دانشگاه علوم پزشکی جندی شاپور اهواز، ایران
AUTHOR
Kramer MS, Barros FC, Demissie K, Liu S, Kiely J, Joseph KS. Does reducing infant mortality depend on preventing low birthweight? An analysis of temporal trends in the Americas. Paediatr Perinat Epidemiol 2005; 19(6):445-51.
1
Van Lerberghe W, Manuel A, Matthews Z, Cathy W. TheWorld Health Report 2005-make every mother and child count. 1st ed. Geneva: World Health Organization; 2005. P. 11.
2
World Health Organization. World health statistics 2010. Geneva: World Health Organization; 2010. P. 61-83.
3
Hogan MC, Foreman KJ, Naghavi M, Ahn SY, Wang M, Makela SM, et al. Maternal mortality for 181 countries, 1980–2008: a systematic analysis of progress towards millenniums development goal. Lancet 2011; 375(9726):1608-23.
4
Ahmed A, Labrallagies M, Knapp B. Prenatal care: a critical component of maternal and child health, university of Maryland. Retrieved. Available at: URL: http: //www cmchswe.umaryland.edu/practice/pregnancy.pdf; 2005.
5
Sehati Shasaei F, Sheibaei F. Lifestyle and its relation with pregnancy outcomes in pregnant women referred to Tabriz Teaching hospitals. Iran J Obstet Gynecol Infertil 2015; 17(131):13-9. (Persian).
6
James DK, Steer PJ, Weiner CP, Gonik B. High risk pregnancy: management options-expert consult. 2nd ed. New York: Elsevier Health Sciences; 2010.
7
Ebn felian A. World Health Organization. J Hospital 2001; 3(1-2):65-8.
8
Majidi S, Moradi A. Investigate the causes of irregular refer pregnant women to get prenatal care in laboring women admitted to teaching hospitals affiliated to the Ministry of Health and Medical Education. J Med Council Islamic Rep Iran 1997; 22(1):32-8. (Persian).
9
Matson S, Lew J. Culturally sensitive prenatal care for Southeast Asians. J Obstet Gynecol Neonatal Nurs 1992; ;21 (1):48-54.
10
Golyan Tehrani SH, Holakoei K, Zarei M. Survey study of effective factors on maternal mortality in Kurdestan province from 1998 to 2002. Hayat 2004; 10(2): 47-54.
11
Hacopy C (1998). Nursing administration. Saint Louis: Mosby Co.16-52.
12
Kessner DM: Screening high-risk populations: a challenge to primary medical care. Community Health 1976, 1(3): 216-225.
13
Kotelchuck M: An evaluation of the Kessner Adequacy of Prenatal Care Index and a proposed Adequacy of Prenatal Care Utilization Index. Am J Public Health 1994, 84(9): 1414-1420.
14
Pourshams, Iran's trading standards, iso9001, iso9002, quality systems. tehran: 2012.
15
Farzandipoor M, Asefzadeh S, Rabeei R. Assessment of consideration on the importance of Medical Records Department standards of Kashan Hospitals. Hayat J 2004; 28(1):28-33. (Persian).
16
Farokhi F, Khadivzadeh T. The quality of midwives provides prenatal care in urban health centers affiliated to Mashhad University of Medical Sciences. Payesh J 2009; 7(3):203-10. (Persian).
17
Syed Alshhdayy F, Ghanei H, Timurid p. Check the quality of services and prenatal care in the healthcare system and the private sector in the city of Sanandaj in 1999. Scientific Journal of Kurdistan University of Medical Sciences, 2009, 4(13): 28-33.
18
Ansari Niaki M, Izadi Sabet F. The quality of prenatal care performance on the basis of existing care standards in health centers. Koomesh 2003; 5 (1, 2): 81-86.
19
Baradaran rezaei M, Mohammad alizadeh S, Piri H, Jabbarzadeh T. Qualify of prenatal care services in the pregnant women attending to the health centers. Nursing & Midwifery Journal. 5, 2007, 14-20.
20
Mir moulaei S.T, Khakbazan Z, Kazemnejad A, Azari M. Prenatal care utilization rate and patients satisfaction. HAYAT 2007; 13(2): 31-40.
21
Andrea B Pembe, Anders Carlstedt, David P Urassa, Gunilla Lindmark, Lennarth Nystrom, Elisabeth Darj.Quality of antenatal care in rural Tanzania: counseling on pregnancy danger signs.2010.
22
Merat S, malekzadeh R, Rezvan H, et al. Hepatitis in Iran. Arc Med J 2003; 4:192-201.
23
Chung Hua, Liu Hsing, Ping Hsueh, Tsa Chichi. Research on factors affecting neonatal tetanus and its prevention through immunization. 1996 Apr. 17(2): 83-6.
24
Mercer BM. Premature rupture of the membrane. In: Petraglia F, Strauss GF, editors. Complicated pregnancy. 4th ed. London: Informa health care; 2007: 713-27.
25
Kallen B, Lundberg G, Aberg A. Relationship Between vitamin use, Smoking, and Nausea and vomiting of pregnancy. Acta Obstet Gynecol Scand 2003; 82: 916-20.
26
Gazmararian IA, Petersen R, Jamieson DJ. Hospitalization during Pregnancy among Managed Care Enrollees. Obstet Gynecol 2002; 100: 94-100.
27
Gandsby R, Barnie-Adshead Am, Jagger C. A prospective Study of nausea and vomiting during pregnancy: Br J Genpract 1993; 43; 245-8.
28
Van Bussel JC, Spitz B, Demyttenaere K. Women mental health before, during and after pregnancy: a population-based controlled cohort study. Birth. 2006. 2006; 33(4): 297-302.
29
Punamaki RL, Repokari L, Vilska S, Poikkeus P, Tiitneu A, Sinkkoneu J, Tulppala M. maternal mental health and medical predictors of infant developmental and health problems from pregnancy to one year: does former infertility matter? Infant Behav Dev. 2006; 29(2): 230-42.
30
Diaz-Olavarrieta C, Paz F, Abuabara K, Martinez Ayala HB, Kolstad K, Palermo T. Abuse during pregnancy in Mexico City. Int J Gynecol Obstet. 2007; 97: 57064.
31
Knudson M, Rozyck GM. Reproductive system trauma. In: Moore E, Feliciano D, Mattox K, ed. Trauma. 5th ed. New York: McGraw Hill, 2004: 851-868.
32
Patterson RM. Trauma in pregnancy. Clin Obstet Gynecol 2005; 27:32-8.
33
Ali J, Yeo A, Gana TJ, Mclellan BA. Predictors of fetal mortality in pregnant trauma patients. J trauma 2007; 42: 782-5.
34
Gashtasbi A, Majlesi F, Rahimi Foroushani A, Nadim A. Quality assessment of prenatal care in kohgiloyeh and boyerahmad province, Iran. Payesh 2002, 1 (1): 7-12.
35
Cunningham F, Leveno K, Bloom S, et al (editors). Williams Obstetrics. New York; McGraw-Hill; 2009: 192.
36
Strafford KE, Shellhaas C, Hade EM. Provider and patient perceptions about dental care during pregnancy. J Matern Fetal Neonatal Med. 2008; 21: 63-71.
37
Kuti O, Osinusi B, Ojengbede O. Assessment of Gestational Age in the Third trimester of pregnancy: Comparison of Symphysio-Fundal Height Measurment with Ultrasound Methods. Trop.J.Obstet & Gynecol, 2003. 20(2), 123-126.
38
Callen M C, Brinkley J E. Controlled trial of fundal height measurement plotted on customized antenatal growth charts. J Obstet & Gynecol 1999; 106(4): 309-17.
39
Saastad E, Ahlborg T, Froen J.F. Low maternal awareness of fetal movement is associated with small for gestational age infants. J Midwifery Wom Heal 2008; 53(4): 345-352.
40
Sharami S.H, Faraji R, Khoramnia S, Dalile Heyrati S.F. Survey the Reason of Maternal Request for Prenatal Ultrasound in Low Risk Pregnancy. Journal of Guilan University of Medical Sciences. 2001; 20 (78): 49-55.
41
Jørgensen FS. Epidemiological studies of obstetric ultrasound examinations in Denmark 1989-1990 versus 1994-1995. Acta Obstet Gynecol Scand. 1999; 78(4):305-9.
42
Leung J L Y, Pang S M C. Ethical Analysis of Non Medical Fetal Ultrasound. Nursing Ethics 2009; 16(5): 637-46.
43
Seltzer V. Women Primary health care. 2th Edition, McGraw-Hill Company: New York, 2000.
44
Sanchez G, Buela-Casal G, Bermudez MP. Influence of gestation period on sexual desire. Psychology in Spain 2004; 3: 14-6.
45
Ozgoli G, Khoushabi K, Valaie N, Dolatian M, Tarverdi M. [Surveying the knowledge and attitude toward sexual relation and its relivant factors in pregnant women referring to primary health care centers in Shaheed Beheshti University of Medical Sciences, 2004]. Pejouhandeh J. 2006; 2(6):137-47. Persian.
46
Bartellas E, Crane JM, Daley M, Bennett KA, Hutchens D. Sexuality and sexual activity during pregnancy. BIOG 2000; 107: 964-8.
47
Kirtiloglu T, Yavuz US. An assessment of oral self care in the student population of a Turkish university. Public Health 2006; 120(10): 953-7.
48
American Academy of periodontology. Baby steps to a healthy pregnancy and on time delivery. Available from: http://WWW.perio.org/consumer/pregnancy.htm. Accessed Jan 20, 2006.
49
Flowles ER. Comparing pregnant women nutritional knowledge to their actual dietary intake. MCN Am J Matern Child Nurs 2002; 27(3):171-7.
50
Landers CM, McElrath TF, Schol TO. Nutrition in adolescent pregnancy. Curr Opin Pediatr 2000; 12(3): 291-6.
51
Meher S, Duley L. (2006) Exercise or other physical activity for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2: CD005942.
52
Rahimi S, Seied Rasoli E. Knowledge and practice of pregnant women about exercise during pregnancy. Iran Nurs J 2003; 17(4): 6-10. [Persian].
53
Clarke PE, Gross H. Women’s behavior beliefs and information sources abour physical exercise in pregnancy. Midwifery 2004; 20(2): 133-141.
54
Mehdizadeh A, Roosta F, Chaichian S, Alaghehbandan R. Evaluation of the impact of birth preparation courses on the health of the mother and the newborn. Am J Perinatol. 2005; 22:7-9.
55
Anya SE, Hydara A, Jaiteh LE. Antenatal care in the Gambia: missed opportunity for information, education and communication. BMC Pregnancy Childbirth. 2008; 8 (9):1-7.
56
Azizzadeh M, Mohammad Alizadeh S, Monshizadeh M, Fasihi.Harandi T. Pregnant women’s points of view regarding to not receiving prenatal care, 2001. Journal of Hormozgan University of Medical Sciences. 2001; 8 (4): 221-226.
57
French MR, Barr SI, Levy-Milne R. Folate intakes and awareness of folate to prevent neural tube defects: a survey of women living in Vancouver, Canada. J Am Diet Assoc 2003; 103(2): 181-5.
58
ORIGINAL_ARTICLE
ارتباط استفاده از شبکههای اجتماعی مجازی و گرایش به فرزندآوری در دانشجویان دانشگاه علوم پزشکی و فردوسی مشهد: مطالعه مقطعی
مقدمه: از آنجا که میزان باروری با عوامل اقتصادی، اجتماعی و فرهنگی مرتبط است، شناسایی دقیق این عوامل ضرورت دارد. ایران در مرحله نزول روند رشد جمعیتی قرار دارد و مواردی که میتواند نقش مؤثری در روند کاهش باروری داشته باشد، پیشرفت تکنولوژی است. نمونهای از تکنولوژی، گسترش صنعت ارتباطات به ویژه شبکههای اجتماعی مجازی است. مطالعه حاضر با هدف تعیین ارتباط بین استفاده از شبکههای اجتماعی مجازی و گرایش به فرزندآوری در دانشجویان دانشگاه علوم پزشکی و فردوسی مشهد انجام شد. روشکار: این مطالعه مقطعی در سال 1394 بر روی 909 نفر از دانشجویان دانشگاه فردوسی و علوم پزشکی مشهد انجام شد. ابزار گردآوری دادهها شامل پرسشنامه اطلاعات فردی، پرسشنامه استفاده از شبکههای اجتماعی در 5 بعد و پرسشنامه گرایش به فرزندآوری بود. تجزیه و تحلیل دادهها با استفاده از نرمافزار آماری SPSS (نسخه 19) و آزمونهای کولموگروف- اسمیرنوف و ضریب همبستگی اسپیرمن انجام شد. میزانp کمتر از 05/0 معنیدار در نظر گرفته شد. یافتهها: در میان ابعاد استفاده از شبکههای اجتماعی، شدت استفاده با درصد میانگین 60، از بقیه ابعاد بیشتر بود. نوع استفاده، شدت استفاده و میزان کنشگری با گرایش به فرزندآوری ارتباط مثبت و معنیداری داشتند (001/0>p) و میزان استفاده و طول مدت عضویت ارتباط معنیداری نداشتند (25/0=p). سن، بُعد خانوار و مقطع تحصیلی نیز با گرایش به فرزندآوری ارتباط منفی و معنیداری داشتند (002/0>p). نتیجه گیری: باروری افراد بیشتر متأثر از ویژگیهای فردی مانند سن و بُعد خانوار است. به نظر میرسد به طور کلی استفاده از شبکههای اجتماعی مجازی بر کاهش تمایل به باروری تأثیری نداشته است.
https://ijogi.mums.ac.ir/article_7608_49105105b658849ca3f5271a2ecee212.pdf
2016-07-22
15
24
10.22038/ijogi.2016.7608
رشد جمعیت
شبکههای اجتماعی مجازی
فرزندآوری
فائزه
قربانی
ghorbani.f69@gmail.com
1
دانشجوی کارشناسی ارشد بهداشت باروری، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.
LEAD_AUTHOR
ناهید
گلمکانی
golmakani n@mums.ac.ir
2
استادیار گروه مامایی، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.
AUTHOR
محمدتقی
شاکری
3
استاد گروه آمار زیستی و اپیدمیولوژی، دانشکده بهداشت، دانشگاه علوم پزشکی مشهد، مشهد، ایران.
AUTHOR
Adibi SM, Arjmand SE, Darvishzadeh Z. The investigation of fertility increase and effective factors on it among the kord clan in Andimeshk. J Iran Soc Dev Stud 2012; 4(1):81-98. (Persian).
1
Chamratrithiong A, Hirschman C, Guest P. A multi- level analysis of the determinants of fertility in the four regions of Thailand. Asia Pac Popul J 1992; 7(1):51-64.
2
Kim C, Laroche M, Tomiuk MA. The Chinese in Canada: a study in ethnic chang with emphasis on gender roles. J Soc Psychol 2004; 144(1):5-29.
3
Erfani A, McQuillan K. Rapid fertility decline in Iran: analysis of intermediate variables. J Biosoc Sci 2008; 40(3):459-78.
4
Jalal Abbasi-Shavazi M, McDonald P. Fertility decline in the Islamic Republic of Iran: 1972-2000. Asian Popul Stud 2006; 2(3):217-37.
5
General population and housing census: preliminary results 2011. population and housing. Available at: URL: http://www.amar.org.ir; 2012.
6
Mobasheri M, Alidosti M, Sorshajani S, Khosravi F, Khalafian P, Jalilian M. Determination of the most important factors influencing the fertility patterns of single child and without child families in Shahr-e-kord city in 2013. J Iilam Univ Med Sci 2013; 21(6):63-70.
7
Fazeli E, Golmakani N, Taghipour A, Shakeri MT. Relationship between value of children and fertility rate in women referred to Mashhad health centers. Iran J Obstet Gynecol Infertil 2014; 17(108):21-7. (Persian).
8
Bigdeli M, Kalantari S, Alizade Agdam MB. Relationship between fertility rate and economic and social development. Soc Welfare Q 2007; 5(21):123-40. (Persian).
9
Barat Dastgerdi N, Sayadi S. Relationship between using Social networks, internet addiction and depression in payamnour universities in Esfahan. J Behav Sci 2013; 10(5):332-41. (Persian).
10
SHahabi M, Bayat G. Goal and motivation membership users in virtual social networks. Cult Commun Stud 2013; 13(20):61-86. (Persian).
11
Pelling EL, White KM. The theory of planned behavior applied to young people's use of social networking web sites. Cyberpsychol Behav 2009; 12(6):755-9.
12
Asgharkia A, Nourimoradabadi Y. Factors associated with the tendency of students to the social network facebook (comparative study of Iranian and American students). Stud Culte Commun 2013; 13(49):181-212. (Persian).
13
Jafarpour M. Conceptualizing and studying the variables effective on how the virtual social networks are accepted and the role non governmental organization play in them. Mobil Strateg Stud Q 2012; 52:109-48. (Persian).
14
Alizadeh E, Mousavizadeh M. The impact of family physician program in reference rate of people in health centers in Mazandaran University of medical sciences. J Med Council Iran 2013; 31(1):9-14. (Persian).
15
Kianpour M, Adlipour S, Ahmadi HM. Interaction in facebook and its impact on modern identity of the youth in Isfahan. Global Med J 2014; 9(2):132-54. (Persian).
16
Enayat H, Parnian L. The study of cultural globalization and tendency to fertility. Woman Soc Q 2013; 4(2):109-36. (Persian).
17
Javadinia SA, Erfanian M, Abedini M, Bijari B. The effects of social networks on academic achievement of students, a study in Birjand University of Medical Sciences. Iran J Med Educ 2012; 12(8):598-606. (Persian).
18
Ghodrati H, Ahmadi A, Mokhtari M, Afrasiabi H. Analysis of social capital and fertility in urban regions of Sabzevar. J Arid Reg Geograp Stud 2011; 1(4):79-94. (Persian).
19
Ektabi R. The Reduction of fertility in Iran and its effective social, cultural and economic factors by emphasizing the family regulation role from 1986 to 1996, Case study: Isfahan city. [Master Thesis]. Isfahan, Iran: Sociology Discipline, Isfahan University; 2005. (Persian).
20
Kalantari S, Bikmohammadi H, Zare Shahabadi A. The effective demographic factors on the Women's fertility in the Yazd city. Women Dev Politics 2004; 3(2):137-56. (Persian).
21
Adlipour S. Sociological analysis of the implications of social networks on social identity young users Isfahan town. [Phd Dissertation]. Isfahan, Iran: Isfahan University; 2013.
22
Soroush M, Bahrani S. A study of relationship between religiosity, sex role attitude, attitude toward children and ideal and actual number of children. Women Dev Politics 2013; 11(2):189-208. (Persian).
23
Saraii H, Ojaghloo S. The generational study of marriage value change in Iran (case of study: women in Zanjan city). J Iran Soc Dev Stud. 2013; 5(4):19-42. (Persian).
24
Mazinani K. Investigate the relationship between the use of social networks and user religious identity. Rahavarde Nour Q 2013; 13(46):22-36. (Persian).
25
Ghoreshi F, Sedaghat K. Study of cultural and social factor’s role in social trust of Tabriz citizens. J Appl Soc 2010; 20(4):79-102. (Persian).
26
Kertzer DI, White MJ, Bernardi L, Gabrielli G. Italy's Path to very low fertility: The adequacy of Economic and second demographic transition theories. Eur J Popul 2009; 25(1):89-115.
27
Manski CF, Mayshar J. Private incentives and social interactions: fertility puzzles in Israel. J Eur Econom Assoc 2003; 1(1):181-211.
28
Rad F, Savabi H. Investigation on tendency to fertility and its related social factors (a case study of married women aged 15 to 50 in Tabriz). J Woman Fam Stud 2016; 3(1):127-55. (Persian).
29
ORIGINAL_ARTICLE
نقش ژنهای BRCA1 و BRCA2 در ابتلاء به سرطان پستان
مقدمه: جهشهای ژنی BRCA1 و BRCA2 در سلولهای رده زایا، باعث خطر ابتلاء به سرطان پستان و تخمدان میشوند. ژنهای BRCA1 و BRCA2، عامل 20% از موارد سرطان پستان ارثی هستند. اکثریت جهشهای موجود در ژنهای BRCA1 و BRCA2 باعث اتمام زودرس پروتئین میشوند. مطالعه حاضر با هدف بررسی نقش جهشهای BRCA1/2 در ابتلاء به سرطان پستان و معرفی برخی جهشهای مرتبط با این ژنها انجام شد. روشکار: در این مطالعه مروری سیستماتیک اطلاعات مربوط به نقش ژنهای BRCA1/2 در ابتلاء به سرطان پستان از طریق جستجو در پایگاههای اطلاعاتیPubMed ، Scopus، MedLine، Web of Science، Science Iranian Database و وب سایتهای مرتبط با موضوع مورد مطالعه با استفاده از کلید واژههایBRCA mutation، BRCA1، BRCA2، سرطان پستان و ایران جستجو شدند. بازه زمانی در انتخاب مقالات از سال 1990 الی 2015 بود. از بین مقالات، به 88 مقاله در متن استناد شد. در انتخاب مقالات بر ژنهای BRCA1 و BRCA2 و اهمیت آن در ابتلاء به سرطان پستان آنها توجه شد. یافتهها: این مقاله مروری اهمیت بیش از پیش شناسایی جهشهای ژنی ناقلین BRCA1 و BRCA2 را در جوامع مختلف و بهویژه ملی را نشان می دهد و لزوم برنامهریزی برای خانوادههایی با تاریخچه فامیلی سرطان پستان و همچنین غربالگری برای جهشهای این دو ژن در برنامههای بالینی کشور کاملاً احساس می شود. نتیجه گیری: ژنهای BRCA1/2 اهمیت و تأثیر زیادی در بروز و پیشرفت سرطان پستان دارند و میتوان این ژنها را به عنوان شاخصهای مولکولی در تشخیص زودهنگام سرطان پستان در نظر گرفت.
https://ijogi.mums.ac.ir/article_7609_fd2388aed020f1732ba62d4a8d6d28d8.pdf
2016-07-22
25
38
10.22038/ijogi.2016.7609
ژن BRCA1
ژن BRCA2
سرطان پستان
محمد مهدی
کوشیار
koshyarmm@mums.ac.ir
1
دانشیار گروه هماتولوژی و انکولوژی، دانشکده پزشکی، دانشگاه فردوسی مشهد، مشهد، ایران.
AUTHOR
محمدرضا
نصیری
nassiryr@um.ac.ir
2
استاد پژوهشکده فناوری زیستی، دانشگاه فردوسی مشهد، مشهد، ایران.
LEAD_AUTHOR
خدیجه
نصیری
khadijeh_nasiri@yahoo.com
3
دانش آموخته دکترای اصلاح نژاد دام (ژنتیک مولکولی)، گروه علوم دامی، دانشکده کشاورزی، دانشگاه فردوسی مشهد. مشهد، ایران.
AUTHOR
Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008; 34(4):378-90.
1
Ripperger T, Gadzicki D, Meindi A, Schlegelberger B. Breast cancer susceptibility: current knowledge and implications for genetic counseling. Eur J Hum Genet 2009; 17(6):722-31.
2
Falagas ME, Zarkadoulia EA, Ioannidou EN, Peppas G, Christodoulou C, Rafailidis PI. The effect of psychosocial factors on breast cancer outcome: a systematic review. Breast Cancer Res 2007; 9(4):R44.
3
Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res 2004; 10(11):3607-13.
4
Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J 2007; 13(4):383-91.
5
Lin Y, Kikuchi S, Tamakoshi K, Kondo T, Niwa Y, Yatsuya H, et al. Active smoking, passive smoking and breast cancer risk: findings from the Japan collaborative cohort study for evaluation of cancer Risk. J Epidemiol 2008; 18(2):77-83.
6
Zabetian Hoseini M, Nassiri MR, Aslaminejad A, Ghafarzadegan K, Mouseghi A, Ghovvati S, et al. Measurment of human progesterone receptor A expression in normal and breast cancer tissue using real-time PCR technigue. Iran J Obstet Gynecol Infertil 2012;15(1):51-9. (Persian).
7
Rohlfs EM, Puget N, Graham ML, Weber BL, Garber JE, Skrzynia C, et al. An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer 2000; 28(3):300-7.
8
Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa-Lyonnet D, Frebourg T, et al. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat 2002; 20(3):218-26.
9
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30(12):e57.
10
Gudmundsdottir KA, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25(43):5864-74.
11
Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108(2):171-82.
12
Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000; 408(6811):429-32.
13
Kurian AW. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol 2010; 22(1):72-8.
14
Antoniou A, Cunningham A, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008; 98(8):1457-66.
15
Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 1999; 4(6):1093-9.
16
Brose MS, Rebbeck TR, Calzone KA, Calzone KA, Stopfer JE, Nathanson KL, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94(18):1365-72.
17
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72(5):1117-30.
18
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62(3):676-89.
19
Kooshyar MM, Nassiri MR, Karimiani EG, Doosti M, Nasiri K, Rodbari Z. Chromosomal analysis and BRCA2*617delT/88delTG and BRIP1(c.2392C>T) mutations of Fanconi anemia in Iranian family, and its correlation to breast cancer susceptibility. J Chem Pharmaceut Res 2015; 7(10):147-53.
20
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266(5182):66-71.
21
Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 1997; 94(11):5605-10.
22
Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 1999; 285(5428):747-50.
23
Folias A, Matkovic M, Bruun D, Reid S, Hejna J, Grompe M, et al. BRCA1 interacts directly with the Fanconi anemia protein FANCA. Hum Mol Genet 2002; 11(21):2591-7.
24
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250(4988):1684-9.
25
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378(6559):789-92.
26
Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thoma NH, et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 2002; 297(5588):1837-48.
27
Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003; 63(7):1449-53.
28
Mazoyer S. Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat 2005; 25(5):415-22.
29
Wang F, Fang Q, Ge Z, Yu N, Xu S, Fan X. Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review. Mol Biol Rep 2012; 39(3):2109-18.
30
Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast‐ovarian cancer. Cancer 2009; 115(10):2222-33.
31
Keshavarzi F, Javadi GR, Zeinali S. BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients. Fam Cancer 2012; 11(1):57-67.
32
Nelson-Moseke AC, Jeter JM, Cui H, Roe DJ, Chambers SK, Laukaitis CM, et al. An unusual BRCA mutation distribution in a high risk cancer genetics clinic. Fam Cancer 2012; 11(1):83-7.
33
Ramus SJ, Friedman LS, Gayther SA, Ponder BA, Bobrow L, van der Looji M, et al. A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nat Genet 1997; 15(1):14-5.
34
Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, et al. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. Ann Oncol 2011; 22(4):964-6.
35
Nomizu T, Matsuzaki M, Katagata N, Kobayashi Y, Sakuma T, Monma T, et al. A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes. Breast Cancer 2012; 22(5):557-61.
36
Easton DF, Ford D. Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers, Breast Cancer Link-age Consortium. Am J Hum Genet 1995; 56(1):265-71.
37
Narod SA, Goldgar D, Cannon-Albright L, WeberB, Moslehi R, Ives E, et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 1995; 64(6):394-8.
38
Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, et al. Double heterozygosity for mutation in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Res Treat 2012; 134(3):1229-39.
39
Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene 2004; 23(38):6445-70.
40
Ferla R, Calo V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, et al. Founder mutations in BRCA1 and BRCA 2 genes. Ann Oncol 2007; 18(6):93-8.
41
Kooshyar MM, Nassiri M, Mahdavi M, Doosti M, Parizadeh A. Identification of germline BRCA1 mutations among breast cancer families in Iran, an experience from Northeastern Iran. Asian Pac J Cancer Prev 2013; 14(7):4339-45.
42
Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14(2):185-7.
43
Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998; 63(1):45-51.
44
Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20(6):1480-90.
45
Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996; 13(1):117-9.
46
Einbeigi Z, Bergman A, Meis-Kindblom JM, Flodin A, Bjursell C, Martinsson T, et al. Occurrence of both breast and ovarian cancer in a woman is a mark er for the BRCA gene mutations: a population-based study from western Sweden. Fam Cancer 2007; 6(1):35-41.
47
Sogaard M, Kruger SK, Cox M, Wozniak E, Hogdall E, Hogdall C, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics in an ovarian cancer case population from Denmark. Clin Cancer Res 2008; 14(12):3761-7.
48
Valarmathi M, Agarwal A, Deo SS, Shukla NK, Satya N. BRCA1 germline mutations in Indian familial breast cancer. Hum Mutat 2002; 21(1):98-9.
49
Pal T, Permuth-Wey J, Holtje T, Sutphen R. BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. Cancer Epidemiol Biomarkers Prev 2004; 13(11):1794-9.
50
Liede A, Jack E, Hegele RA, Narod SA. A BRCA1 mutation in native North American families. Hum Mutat 2002; 19(4):460.
51
Clark SL, Rodriguez AM, Snyder RR, Hankins GD, Boehning D. Structure-function of the tumor suppressor BRCA1. Comput Struct Biotechnol J 2012; 1(1):e201204005.
52
Thompson D, Easton D, Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 2002; 11(4):329-36.
53
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin–cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98(23):1694-706.
54
Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12(1):68-78.
55
Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008; 8:155.
56
Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, et al. Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April 2007. Cancer 2008; 113(10):2627-37.
57
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25(11):1329-33.
58
Mohamad HB, Apffelstaedt JP. Counseling for male BRCA mutation carriers: a review. Breast 2008; 17(5):441-50.
59
Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22(4):735-42.
60
Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8(12):3776-81.
61
Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20(9):2310-8.
62
Vaziri SA, Krumroy LM, Elson P, Elson P, Budd GT, Darlington G, et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 2001; 7(7):1937-45.
63
Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 2000; 18(21 Suppl):107S-12.
64
Adem C, Reynolds C, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ, et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 2003; 97(1):1-11.
65
van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, et al. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 2006; 59(6):611-7.
66
Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, et al. The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004; 64(3):830-5.
67
Verhoog LC, Brekelmans CT, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 1999; 17(11):3396-402.
68
Senst N, Llacuachaqui M, Lubinski J, Lynch H, Armel S, Neuhausen S, et al. Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation. Clin Genet 2012; 84(1):43-6.
69
Cortesi L, Turchetti D, Bertoni C, Bellei R, Mangone L, Vinceti M, et al. Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations. Genes Chromosomes Cancer 2000; 27(2):130-5.
70
Neamatzadeh H, Shiryazdi SM, Kalantar SM. BRCA1 and BRCA2 mutations in Iranian breast cancer patients: a systematic review. J Res Med Sci 2015; 20(3):284-93.
71
Saleh-Gohari N, Mohammadi-Anaie M, Kalantari-Khandani B. BRCA1 gene mutations in breast cancer patients from Kerman Province, Iran. Iran J Cancer Prev 2012; 5(4):210-5.
72
Yassaee VR, Zeinali S, Harirchi I, Jarvandi S, Mohagheghi MA, Hornby DP, et al. Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early‑onset breast cancer. Breast Cancer Res 2002; 4(4):R6.
73
Mehdipour P, Hosseini-Asl S, Savabi-E A, Habibi L, Alvandi E, Atri M. Low frequency of 185delAG founder mutation of BRCA1 gene in Iranian breast cancer patients. J Cancer Mol 2006; 2(3):123-7.
74
Fattahi MJ, Mojtahedi Z, Karimaghaee N, Talei AR, Banani SJ, Ghaderi A. Analysis of BRCA1 and BRCA2 mutations in southern Iranian breast cancer patients. Arch Iran Med 2009; 12(6):584‑7.
75
Ghorbanpoor S, Bidmeshkipoor A, Mirmomeni MH, Khazaee S. Role of BRCA1 gene mutations in sporadic cases of breast cancer in Kermanshah. Sci J Kurdistan Univ Med Sci 2010; 14(4):60-71. (Persian).
76
Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, et al. A prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011; 29(13):1664-9.
77
Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364(25):2381-91.
78
Nooshinfar E, Bashash D, Khodakarami N, Mohamadi G, Taghavi A, Shahani M, et al. Melatonin and its importance in Breast cancer prevention and treatment (A purposed review article). Iran J Obstet Gynecol Infertil 2014; 17(118):10-21. (Persian).
79
Akbari ME, Khayamzadeh M, Khoshnevis SJ, Nafisi N, Akbari A. Five and ten years survival in breast cancer patients mastectomies vs. breast conserving surgeries personal experience. Iran J Cancer Prev 2012; 1(2):53-6.
80
Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006; 118(9):2281-4.
81
Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009; 69(9):3850-5.
82
Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010; 468(7320):98-102.
83
Khadivi R, Harrirchi I, Akbari ME. Ten year breast cancer screening and follow up in 52200 women in Shahre-Kord, Iran (1997-2006). Iran J Cancer Prev 2008; 1(2):73-7.
84
Sadjadi A, Sadjadi M, Mohagheghi MA, Mousavi-Jarrahi A, Malekezadeh R, Parkin DM. Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev 2005; 6(3):359-63.
85
Bougie O, Weberpals JI. Clinical considerations of BRCA1‑ and BRCA2‑mutation carriers: a review. Int J Surg Oncol 2011; 2011:374012.
86
Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4(9):665-76.
87
Xu B, Kim ST, Kastan MB. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001; 21(10):3445-50.
88